Rigel to Present at Bank of America Merrill Lynch Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 5, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 10th at 10:00 a.m. PT.
The presentation will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that has completed Phase 1 clinical trials for asthma.
Contact: Ryan MaynardPhone: 650.624.1284Email: email@example.com
SOURCE Rigel Pharmaceuticals, Inc.